Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Acquisition [Axis] Business Acquisition [Axis] Olumiant® Olumiant [Member] Olumiant [Member] Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net income (loss) Total reclassifications, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Number of pending lawsuits Loss Contingency, Pending Claims, Number Schedule of asset acquisitions Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Deferred tax assets Deferred Income Tax Assets, Net Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Net investment (gains) losses Gain (Loss) on Investments Other diabetes Other Diabetes [Member] Other Diabetes [Member] Business Combinations Business Combinations Policy [Policy Text Block] Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Damages awarded, value Loss Contingency, Damages Awarded, Value Foreign currency exchange contracts Foreign Exchange Contract [Member] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Number of plaintiffs Loss Contingency, Number of Plaintiffs Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. [Member] Rigel Pharmaceuticals, Inc. Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Asset Acquisition [Table] Asset Acquisition [Table] Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Net income Net income Net income Net Income (Loss) Attributable to Parent 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Document Information [Line Items] Document Information [Line Items] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Equity Component [Domain] Equity Component [Domain] Scenario [Axis] Scenario [Axis] Cost of common stock in treasury Treasury Stock, Common, Value Asset impairment and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Total Debt Securities, Available-for-Sale Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Total other liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Alternative investments, unfunded commitments, payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Summary the contractual maturities of our investments in debt securities measured at fair value Debt Securities, Available-for-Sale [Table Text Block] Innovent Biologics, Inc. Innovent Biologics, Inc. [Member] Innovent Biologics, Inc. Other neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Costs, expenses, and other: Costs and Expenses [Abstract] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Legal Entity [Axis] Legal Entity [Axis] Long-term debt Long-Term Debt, Excluding Current Maturities Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Byetta Byetta [Member] Byetta Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Accrued retirement benefits (Note 8) Liability, Defined Benefit Plan, Noncurrent Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Other current liabilities Derivative Liability, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of significant milestones and revenue recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Basaglar® Basaglar Basaglar [Member] Basaglar [Member] Short-term investments Debt Securities, Available-for-Sale, Current Document Type Document Type Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Contingent value right, monthly reduction (in cents per share) Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Severance Severance Costs Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Effective portion of cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Entity Shell Company Entity Shell Company Other, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest Financial Instrument [Axis] Financial Instrument [Axis] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Schedule of amounts recorded for contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Precision Biosciences, Inc. Precision Biosciences, Inc. [Member] Precision Biosciences, Inc. Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Earnings per share: Earnings Per Share [Abstract] Equity securities Equity Securities, FV-NI, Current Forward-starting interest rate swaps Interest Rate Swap [Member] Taltz® Taltz [Member] Taltz [Member] Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Investments (Note 6) Noncurrent investments Long-Term Investments Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Employee compensation Employee-related Liabilities, Current Asset-backed securities Asset-Backed Securities [Member] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Verzenio® Verzenio [Member] Verzenio [Member] Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Interest cost Defined Benefit Plan, Interest Cost Other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Income Tax Contingency [Table] Income Tax Contingency [Table] Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Schedule of fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Derivative Contract [Domain] Derivative Contract [Domain] Net Investment Hedges Net Investment Hedging [Member] Entity Registrant Name Entity Registrant Name China CHINA Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Entity Address, City or Town Entity Address, City or Town Retirement Benefits Retirement Benefits [Text Block] Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Other oncology Other Oncology [Member] Other Oncology [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Inventory write-down Inventory Write-down Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Brazil BRAZIL Common Stock in Treasury Treasury Stock, Common [Member] Defined Benefit Pension Plans Pension Plan [Member] Financial Instruments Fair Value Disclosures [Text Block] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Trading Symbol Trading Symbol Entity File Number Entity File Number Foreign currency-denominated notes Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Acquired in-process research and development Acquired In-process Research And Development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Research and development Research and Development Expense Purchases of short-term investments Payments to Acquire Short-Term Investments Description of Derivative Risk Management Derivatives, Policy [Policy Text Block] Effective income tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Derivative liability, notional amount Derivative Liability, Notional Amount Acquisitions Business Combination Disclosure [Text Block] Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Revenue (Note 2) Revenue Revenues Income Taxes Income Tax Disclosure [Text Block] Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Alimta® Alimta [Member] Alimta [Member] Basic (in dollars per share) Earnings Per Share, Basic Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Total Eli Lilly and Company shareholders' equity Stockholders' Equity Attributable to Parent Cash and cash equivalents at January 1 Cash and Cash Equivalents at June 30 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Prepaid expenses and other Prepaid Expense, Current Erbitux® Erbitux [Member] Erbitux [Member] Entity Interactive Data Current Entity Interactive Data Current 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Amount of receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Dividends paid Payments of Dividends Retained Earnings Retained Earnings [Member] Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-Term Investments Common Stock Common Stock [Member] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Purchases of common stock Payments for Repurchase of Common Stock Contingent consideration liability, other noncurrent liabilities Business Combination, Contingent Consideration, Liability Short-term commercial paper borrowings Commercial Paper Costs, expenses, and other Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net Class of Stock [Axis] Class of Stock [Axis] Buy US Dollar Sell Chinese Yuan Buy US Dollar Sell Chinese Yuan [Member] Buy US Dollar Sell Chinese Yuan Immunology Immunology [Member] Immunology [Member] Statement [Table] Statement [Table] Product Liability Product Liability [Member] Product Liability Document Quarterly Report Document Quarterly Report Current Assets Assets, Current [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Proceeds from sales of noncurrent investments Proceeds from Sale of Long-Term Investments Asset Acquisition [Domain] Asset Acquisition [Domain] Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Accounts receivable, net of allowances of $19.2 (2022) and $22.5 (2021) Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Litigation Case Type [Domain] Litigation Case [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Number of claims dismissed Litigation, Claims Dismissed, Number Litigation, Claims Dismissed, Number Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Other–net, (income) expense (Note 11) Other–net, (income) expense Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Marketing, selling, and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Unrealized gross losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Net product revenue Product [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Other Other Product, Total [Member] Other Product, Total [Member] Net purchases of property and equipment Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Implementation of New Financial Accounting Standard New Accounting Pronouncements, Policy [Policy Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Document Information [Table] Document Information [Table] Goodwill Goodwill Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Unrealized Net Gains (Losses) on Securities Unrealized net gains/losses on securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Collaborative arrangement, rights and obligations, percentage (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income taxes (Note 7) Tax benefit Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Deferred tax liabilities Deferred Income Tax Liabilities, Net Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Net change in short-term borrowings Proceeds from Short-Term Debt Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Cost of sales Cost of Goods and Services Sold Purchases of in-process research and development Purchased In-process Research And Development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Cyramza® Cyramza [Member] Cyramza [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Diabetes Diabetes [Member] Diabetes [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Other Other Product [Member] Other Product [Member] Recognized actuarial loss Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Buy British Pounds and Sell U.S. Dollars Buy British Pound and Sell US Dollars [Member] Buy British Pound and Sell US Dollars [Member] Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Common stock Common Stock, Value, Issued Carrying Amount Reported Value Measurement [Member] Derivatives used in net investment hedge, net of tax Derivatives used in Net Investment Hedge, Net of Tax Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Current Liabilities Liabilities, Current [Abstract] Contingent value right, additional price per share (up to) (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Summary of the fair value of available-for-sale securities in an unrealized gain or loss position Unrealized Gain (Loss) on Investments [Table Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Acquisitions Asset Acquisition [Text Block] Cash Flow Hedging Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Fair Value Hedging Fair Value Hedging [Member] Acquired IPR&D Expense Payments for Asset Acquisitions Payments for Asset Acquisitions Other comprehensive income (loss), net of tax (Note 10) Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary certain fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Litigation Case [Axis] Litigation Case [Axis] Cymbalta® Cymbalta [Member] Cymbalta [Member] Unrealized gross gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other noncurrent assets Other Assets, Noncurrent Milestone Payments, Capitalized as Intangible Assets Milestone Payments, Capitalized As Intangible Assets [Member] Milestone Payments, Capitalized As Intangible Assets Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Japan JAPAN Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of the amounts recognized for assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net of accumulated depreciation of $10,119.7 (2022) and $9,976.7 (2021) Property, Plant and Equipment, Net Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Repayments of long-term debt Repayments of Long-Term Debt Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Cash dividends declared Dividends Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Other–net, (income) expense Other (income) expense Other Nonoperating Income (Expense) Long-term debt, including current portion Long-term debt, including current portion Long-Term Debt 1.700% Notes due 2049 1.700% Notes Due 2049 [Member] 1.700% Notes due 2049 [Member] Acquired in-process research and development and development milestones (Note 3) Acquired in-process research and development and development milestones Acquired In-Process Research And Development And Development Milestones Acquired In-Process Research And Development And Development Milestones Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss (Note 10) Accumulated Other Comprehensive Income (Loss), Net of Tax Non-CHINA Non-CHINA [Member] Non-CHINA Common Stock (no par value) Common Class A [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents (Note 6) Cash and Cash Equivalents, at Carrying Value Available-for-sale, percentage of nonperforming assets Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets. Equity securities, net unrealized gains (losses) Net investment (gains) losses on equity securities (Note 6) Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Income taxes payable Taxes Payable, Current Other immunology Other Immunology [Member] Other Immunology [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Schedule of net pension and retiree health benefit (income) cost Schedule of Net Benefit Costs [Table Text Block] Cash dividend declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Summary certain fair value information, assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 Derivative asset, notional amount Derivative Asset, Notional Amount Equity method investments Other Long-Term Investments COVID-19 Antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc [Member] BioMarin Pharmaceutical Inc Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Basis of Presentation and Implementation of New Financial Accounting Standard Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Short-term investments (Note 6) Short-Term Investments Other noncurrent assets Derivative Asset, Noncurrent Business Combination and Asset Acquisition [Abstract] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] U.S. government and agency securities US Government Agencies Debt Securities [Member] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] 0.500% Notes due 2033 .5000% Notes Due 2033 [Member] .5000% Notes Due 2033 Liabilities and Equity Liabilities and Equity [Abstract] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] 0.625% Notes due 2031 .625% Notes Due 2031 [Member] .625% Notes due 2031 [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories Inventory, Net Accounts payable Accounts Payable, Current Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Sell Euro Sell Euro [Member] Sell Euro [Member] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Insulin Insulin [Member] Insulin Entity Filer Category Entity Filer Category Eli Lilly and Company Shareholders' Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic U.S. UNITED STATES Employee benefit trust Common Stock, Shares Held in Employee Trust Commitments and Contingencies (Note 9) Commitments and Contingencies Security Exchange Name Security Exchange Name Employee Benefit Trust Trust for Benefit of Employees [Member] Derivative, notional amount Derivative, Notional Amount Tyvyt® TYVYT [Member] TYVYT Service cost Defined Benefit Plan, Service Cost Short-term borrowings and current maturities of long-term debt Debt, Current Other Liabilities Liabilities, Noncurrent [Abstract] Cover [Abstract] Cover [Abstract] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Purchases of noncurrent investments Payments to Acquire Long-Term Investments Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Revenue Revenue from Contract with Customer [Text Block] Cash acquired Cash Acquired from Acquisition Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Noncontrolling Interests Noncontrolling Interest [Member] Forecast Forecast [Member] Other receivables Derivative Asset, Current Milestone Payments, Success-based Regulatory and Sales-based Milestone Payments, Success-based Regulatory And Sales-based [Member] Milestone Payments, Success-based Regulatory And Sales-based Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Total liabilities and equity Liabilities and Equity Cost Portion at Other than Fair Value Measurement [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Stock repurchase program, remaining authorized amount Stock Repurchase Program, Remaining Authorized Repurchase Amount 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Outside U.S. Non-US [Member] Sales rebates and discounts Sales Rebates And Discounts Sales Rebates And Discounts Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Cash paid for acquisitions, net of cash acquired (Note 3) Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Cialis® Cialis [Member] Cialis [Member] Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Diluted (in dollars per share) Earnings Per Share, Diluted Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Total current liabilities Liabilities, Current More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Long-term income taxes payable Accrued Income Taxes, Noncurrent Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Corporate debt securities Corporate Debt Securities [Member] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Royalty Agreement Terms Royalty Agreement Terms [Member] Entity Address, Address Line One Entity Address, Address Line One Benefit (expense) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Other financing activities, net Proceeds from (Payments for) Other Financing Activities Contract liabilities Contract with Customer, Liability Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Intangible asset impairment Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Product and Service [Axis] Product and Service [Axis] 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Europe Europe [Member] Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Retirement Plan Type [Axis] Retirement Plan Type [Axis] Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Equity [Abstract] Equity [Abstract] Humalog® Humalog [Member] Humalog [Member] Jardiance Jardiance [Member] Jardiance [Member] Other receivables Other Receivables, Net, Current Entity Tax Identification Number Entity Tax Identification Number Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Forteo® Forteo [Member] Forteo [Member] Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Dividends payable Dividends Payable, Current Effective Portion of Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Roche Roche [Member] Roche [Member] Schedule of components of the charges included in asset impairment, restructuring, and other special charges Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Interest income Investment Income, Interest Research and Development Expenses and Acquired In-Process Research and Development (IPR&D) and Developmental Milestones Research and Development Expense, Policy [Policy Text Block] Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Buy U.S. Dollars Sell Euros Buy Us Dollar Sell Euro [Member] Foreign Currency Forward commitment to Buy US dollar Sell euro Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity [Domain] Entity [Domain] City Area Code City Area Code Assets Assets [Abstract] Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Retirement Benefits [Abstract] Retirement Benefits [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Other securities Other Debt Obligations [Member] Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Alternative investments, unfunded commitments Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Schedule of activity related to our available-for-sale securities Gain (Loss) on Securities [Table Text Block] Mortgage-backed securities Collateralized Mortgage-Backed Securities [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Other noncurrent liabilities Other Liabilities, Noncurrent Interest Rate Contracts Interest Rate Contract [Member] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted Description of Derivative Activity Volume Percent Description of Derivative Activity Volume Percent Zyprexa® Zyprexa [Member] Zyprexa [Member] Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Other noncurrent liabilities Derivative Liability, Noncurrent